A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants
A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Comparing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of Rozanolixizumab in Japanese, Chinese and Caucasian Healthy-Volunteer Study Participants
Sponsor: UCB Biopharma S.P.R.L.
A PHASE1 clinical study on Healthy-volunteers, this trial is completed. The trial is conducted by UCB Biopharma S.P.R.L. and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE1
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UCB Biopharma S.P.R.L.
For direct contact, visit the study record on ClinicalTrials.gov .